Sacituzumab govitecan monotherapy (TNBC ≥2L; HR+/HER2- ≥3L)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-SACITUZUMAB-GOVITECAN`

ID	`REG-SACITUZUMAB`
Type	Regimen
Status	pending_clinical_signoff
Diseases	None declared
Sources	`SRC-ESMO-BREAST-METASTATIC-2024` `SRC-NCCN-BREAST-2025`

Notes

ASCENT: superior to physician-choice chemo in pretreated metastatic TNBC. TROPiCS-02: HR+/HER2- ≥3L. Trop-2 expression universal — not required pre-test.

Used By

Indication

IND-BREAST-TNBC-2L-SACITUZUMAB - IND-BREAST-TNBC-2L-SACITUZUMAB